LakeShore Biopharma Co., Ltd
LSBNASDAQHealthcare
$0.63
+$0.00(+0.00%)
Market Cap$25840359
P/E Ratio—
52W High$8.6
52W Low$0.574
LakeShore Biopharma Co., Ltd (LSB) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · LSB · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($0.10B) | ($0.43B) | ($0.15B) | ($0.11B) | ($0.21B) |
| Depreciation & Amort. | $0.04B | $0.04B | $0.04B | $0.03B | $0.03B |
| Stock-Based Comp. | $0.01B | $0.01B | $0.00B | $0.01B | $0.08B |
| Change in Working Capital | ($0.12B) | ($0.05B) | ($0.09B) | ($0.14B) | ($0.15B) |
| Net Cash from Operations | ($0.12B) | ($0.30B) | ($0.18B) | ($0.17B) | ($0.25B) |
| Investing Activities | |||||
| Capital Expenditure | ($0.02B) | ($0.04B) | ($0.06B) | ($0.30B) | ($0.10B) |
| Purchases of Investments | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Sales of Investments | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Cash from Investing | ($0.02B) | ($0.04B) | ($0.06B) | ($0.30B) | ($0.10B) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | ($0.00B) | ($0.08B) | $0.10B | $0.36B | $0.01B |
| Net Cash from Financing | ($0.00B) | $0.21B | $0.32B | $0.36B | $0.74B |
| Free Cash Flow | |||||
| Free Cash Flow | ($0.14B) | ($0.34B) | ($0.24B) | ($0.30B) | ($0.35B) |
| FCF Margin %(computed) | -22.58% | -59.20% | -34.85% | -59.56% | -136.76% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · CNY · B
Explore more LakeShore Biopharma Co., Ltd data
About LakeShore Biopharma Co., Ltd (LSB) Cash Flow Statement
LakeShore Biopharma Co., Ltd generated operating cash flow of ($0.12B) and free cash flow of ($0.14B) for 2025 — a FCF margin of -22.58%. Capital expenditure was ($0.02B).
Frequently asked questions
LSB · 4 questionsLakeShore Biopharma Co., Ltd generated free cash flow of ($0.14B) for 2025, up 59.1% year-over-year.
LSB free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10